Aptamer Group Plc · LSE:APTA
Aptamer — H1 FY2024 Earnings Presentation
26 slides from Aptamer's earnings presentation, March 2024
Slide 1: Interim Results Presentation for 6 months to 31 Dec 2023
Interim Results Presentation for 6 months to 31 Dec 2023 • Dr Arron Tolley • Andrew Rapson Chief Technical Officer Chief Financial Officer [email protected] [email protected] • Dr David Bunka Chief Scientific Officer [email protected]
Slide 2: Disclaimer
DISCLAIMER Private and Confidential - for personal use only and not for distribution This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking s
Slide 3: Presentation overview
Presentation overview 01 | Introduction 02 | H1 overview: Operational & financial 03 | Post-period update: Operational & technical progress 3
Slide 4: Presentation team
Presentation team Dr Arron Tolley Dr David Bunka Andrew Rapson Chief Technical Officer Chief Scientific Officer Chief Financial Officer ‒ Co-founded Aptamer Group in 2008 ‒ Co-founded Aptamer Group in 2008 ‒ Over 20 years of finance experience, ‒ Globally-recognised technical & ‒ Globally-recognised
Slide 5: Introduction to Aptamer Group
Introduction to Aptamer Group
Slide 6: About Aptamer Group
About Aptamer Group Historical co-existing relationships with 15 of Top 20 pharma companies 1 37 team members 2 New custom-equipped facilities delivered in 2022 - Started trading in 2012 - Headquartered in York, UK 42 partners across - AIM IPO in Dec 2021 the globe in FY 2023 - Proprietary Optimer p
Slide 7: Affinity ligand technology market
Affinity ligand technology market Affinity ligands are used in a wide range of applications This market was historically dominated by antibodies, but alternative affinity ligands have emerged to address needs that antibodies cannot fulfil Aptamers are an important disruptive platform within the affi
Slide 8: The Optimer platform - an enabling technology
The Optimer® platform - an enabling technology Targets Applications Therapeutics • Therapeutic inhibitors & modulators Multiple Optimer® libraries • Targeted delivery vehicles Small as starting materials for each discovery molecules 3 discovery processes tuned for target type to increase success in
Slide 9: Aptamer Group USPs
Aptamer Group USPs Tailored approach: Multiple selection strategies, optimised for different target types High-throughput platform: Efficient processing & rapid discovery of new functional molecules Know-how: Team of scientists with 70+ years of Optimer expertise 9
Slide 10: H1 FY24 Operational review
Hi FY24 Operational review @ aptamer
Slide 11: Strategy for revenue generation & technical delivery
Strategy for revenue generation & technical delivery The new Board raised £3.5m after expenses to support and direct the team to revenue generation and technical delivery with an intensive focus on reducing the cost base while maintaining the ability to win sales and deliver projects. New characteri
Slide 12: Key highlights for H1 FY24
Key highlights for H1 FY24 Aptamer Group Refreshed Board with pre-IPO Chairman and co-founder returning to support and direct the team to revenue generation & technical delivery (Aug 2023). Completed the reset of the fixed cost base to £3.5 million per annum, whilst maintaining the ability to win sa
Slide 13: Developed broader service offering for post-Optimer validation
Developed broader service offering for post-Optimer® validation A broader portfolio of validation assays has been established, along with expertise in assay development, to support partners . These services are being offered to customers to increase project revenue and improve the translation of Opt
Slide 14: H1 FY24 Financial review
Hi FY24 Financial review @ aptamer
Slide 15: Income statement
Income statement ‒ Group revenue of £0.3m (H1FY23: £1.0m) ‒ £0.8m deals signed in December 2023 ‒ Adjusted EBITDA loss of £1.8m (H1FY23: £2.5m) ‒ Cost base reset to £3.5m per annum completed in September 2023 Six months Six months ‒ Headcount at 31 December 2023 of 37 (46 at 30 June 2023) ended ende
Slide 16: Balance sheet
Balance sheet As at As at As at ‒ Cash at 31 Dec 2023 of £1.8m (June 2023: £0.2m) 31 Dec 23 31 Dec 22 30 Jun 23 ‒ Cash as at 29 February 2024 was £1.8m following receipt of R&D £’000 £’000 £’000 tax credit payment from HMRC Other intangible assets 99 339 70 ‒ Net assets of £2.0m (June 2023: £0.3m).
Slide 17: Cash flow
Cash flow ‒ Net cash outflow from operations of £1.8 million (H1FY23: £2.9m) reflecting the adjusted EBITDA loss on a lower cost base compared to the prior period ‒ Reduction in purchase of assets where prior period included fitout of new laboratory and office space ‒ Net £3.5m raised during August
Slide 18: Post-period highlights
Post-period highlights @ aptamer
Slide 19: Post-period operational highlights
Post-period operational highlights Aptamer Group Updated financial position as at 27 March 2024, £1.3m in production, £2.9m opportunity pipeline. Technical progress to date in developing the new affinity ligand platform, Optimer®+, was made, highlighting the improved results compared to the current
Slide 20: Technical progress
Technical progress @ aptamer
Slide 21: Progress: Optimer+ a new affinity ligand platform
Progress: Optimer®+ a new affinity ligand platform Optimer®+ Recombinant Traditional Protein Scaffolds Bicyclic peptides Hybrid Protein Optimer® Antibodies Antibodies (synthetic) (synthetic) Nucleic Acid (synthetic) (synthetic) (synthetic) Camlid Affimer Darpins Optimer®+ will: • Broaden application
Slide 22: Progress: Exemplification data of Optimer-Fc performance in IHC
Progress: Exemplification data of Optimer®-Fc performance in IHC Immunohistochemistry (IHC) is used globally in hospital pathology labs and research labs ($2.3Bn 1 market) and is the gold standard in clinical diagnostics. Many antibodies do not work in IHC, so there is a need for new and improved bi
Slide 23: Progress: Optimer-enabled drug delivery
Progress: Optimer®-enabled drug delivery Targeted drug delivery to the site-of-action in the body remains a major challenge for gene therapy, chemotherapy and radioligands. Developed Optimer® delivery vehicles for fibrotic liver disease have been validated for gene therapy in lab- based experiments
Slide 24: Summary & outlook
Summary & outlook Q) aptamer
Slide 25: Summary & outlook
Summary & outlook New refreshed Board with a focus on delivering shareholder value through technical Partners across multiple sectors of the life sciences output and revenue generation. Cost base reset with ongoing tight cost discipline offers runway into FY25. Commercial team worked hard and increa
Slide 26: Contact details
W: aptamergroup.com E: [email protected] T: +44 (0) 1904 217404